Verona Pharma PLC (LON:VRP, NASDAQ:VRNA) has said it is to present to a leading industry conference data from a phase IIb trial of its drug candidate for chronic obstructive pulmonary disease (COPD).
Delegates at the virtual European Respiratory Society International Congress will be provided subgroup analysis from Verona’s phase IIb trials of nebulised ensifentrine.
The data was first reported in January and March this year. It demonstrated the drug improves lung function in moderate to severe COPD patients regardless of smoking status or history of chronic bronchitis over four weeks.
It worked given as a single therapy or in combination with tiotropium, a long-acting anti-muscarinic bronchodilator.
As well as the presentation on September 8 by Tara Rheault, vice president, R&D, there will be a poster outlining the findings.
Abstracts are available on the ERS website and will be published in a supplement of next month’s edition of the peer-reviewed European Respiratory Journal.